Renaissancere Holdings

RNR · NYSE

$354.33+$2.80 (+0.80%)TodayMarket closed · Oct 20, 7:41 PM ET

Prev close $351.53

RNR analyst rating

HoldConsensus of 14 analysts over the last 12 months. 21% rate it a buy.

Strong buy0
Buy3
Hold11
Underperform0
Sell0

12-month price target · 19 analysts

Average $339.03 (−4.3% downside)

Low: $126.36
Now: $354.33
High: $443.10

Upgrades and downgrades

The latest rating actions, newest first

RNR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Oct 12, 2026	Maintains	Equal-Weight	$331.00 → $319.00	60%
TD Cowen	Oct 12, 2026	Maintains	Hold	$315.00 → $320.00	54%
JP Morgan	Oct 9, 2026	Maintains	Neutral	$360.00 → $355.00	81%
RBC Capital	Sep 22, 2026	Initiates	Sector Perform	$365.00	44%
Keefe, Bruyette & Woods	Jul 28, 2026	Maintains	Market Perform	$342.00 → $350.00	68%
UBS	Jul 27, 2026	Maintains	Neutral	$342.00 → $349.00	68%
B of A Securities	Jul 23, 2026	Maintains	Buy	$410.00 → $438.00	60%
Evercore ISI Group	Jul 23, 2026	Maintains	In-Line	$320.00 → $330.00	56%
JP Morgan	Jul 20, 2026	Maintains	Neutral	$329.00 → $360.00	57%
Evercore ISI Group	Jul 10, 2026	Maintains	In-Line	$309.00 → $320.00	56%

The case for and against

Updated Oct 15, 2026

Bull case

RenaissanceRe Holdings is well positioned to compound value because its 2026E EPS estimate rises to $47.80, driven by lower projected 3Q26E catastrophe losses, while 2027E EPS of $40.00 still benefits from higher net investment income despite softer underwriting income. Its managed investments plus cash were 3.2x shareholders’ equity at 2Q26, and with a 5%+ book yield and high-quality fixed-income assets leveraged to equity, the company can sustain low-teens ROEs even as pricing remains challenging. The firm’s disciplined capital management, including expected 10%+ annual buybacks and a history of 9.6% CAGR BVPS growth since 2015, supports double-digit BVPS growth and helps limit downside.

Bear case

RenaissanceRe Holdings is facing a deteriorating setup as softening property reinsurance pricing, rising competition after 2022, and expected further cuts through 2028 threaten the core business that drives most underwriting income. Although management is best-in-class and capital partners provides fee income, the company still carries elevated catastrophe exposure, making earnings and book value highly volatile, while the Casualty & Specialty segment is currently posting underwriting losses and only modest improvement is expected. With 1H26 net written premiums down 24% versus 1H25, 2025 payout ratio at 92%, and buybacks already absorbing excess capital, the path to meaningful growth looks limited as underwriting margins normalize and investor sentiment remains cautious.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.